Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07436611 · ClinicalTrials.gov registry record · Phase 2
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
A Phase 2 study, sponsored by AFT Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07436611 is a Phase 2 study that has not yet begun recruiting, run by AFT Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT07436611, a Phase 2 study, has not yet begun recruiting, sponsored by AFT Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is: Will rapamycin cream and laser treatment show a greater improvement in appearance of port wine birthmarks, compared to treatment with placebo cream and laser? Researchers will compare two concentrations of rapamycin cream (0.6% or 1.0%) with placebo treatment to see if appearance is improved following 12 weeks of treatment. Participants will receive laser treatment of their port wine birthmark and then apply the rapamycin or placebo cream daily for 12 weeks. Patients will visit the clinic every 4 weeks for checkups and tests.
Interventions
- DRUG Rapamycin cream
- PROCEDURE Pulsed dyed laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-08 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07436611
The ClinicalTrials.gov registry entry for NCT07436611 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AFT Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rapamycin cream is the first listed.
NCT07436611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07436611 about?
NCT07436611 is a clinical study titled "Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains". The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is: Will rapamycin cream and laser treatment show a greater improvement in appearance of p...
What is the current status of trial NCT07436611?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-08. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07436611?
The interventions under investigation include: Rapamycin cream (DRUG), Pulsed dyed laser (PROCEDURE).
Who is sponsoring clinical trial NCT07436611?
This trial is sponsored by AFT Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.